Sarcoma

Oscar Martinez-Tirado

PRINCIPAL INVESTIGATORS
  • Xavier Garcia del Muro Solans
CLINICAL RESEARCHERS
  • Francesc Xavier Sanjuan Garriga
  • Juan Jesus Martin Liberal
POSTDOCTORAL RESEARCHERS
  • Mariona Chicón Bosch
  • Laura Santana Viera
PREDOCTORAL RESEARCHERS
  • Paola Monaco
  • Sara Sanchez Serra
SCIENTIFIC SUPPORT
  • Roser Lopez Alemany
  • Susana Maqueda Marcos
Cancer
Oncobell

Scientific production

18

PAPERS

Impact factor: 221,128

9 PUBLICATIONS IN FIRST DECILE

14 PUBLICATIONS IN FIRST QUARTILE

8 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Gillessen S, Sauve N, Collette L, Daugaard G, de Wit R, Albany C, Tryakin A, Fizazi K, Stahl O, Gietema JA, De Giorgi U, Cafferty FH, Hansen AR, Tandstad T, Huddart RA, Necchi A, Sweeney CJ, Garcia Muro X, Heng DYC, Lorch A, Chovanec M, Winquist E, Grimison P, Feldman DR, Terbuch A, Hentrich M, Bokemeyer C, Negaard H, Fankhauser C, Shamash J, Vaughn DJ, Sternberg CN, Heidenreich A, Beyer J, Int Germ Cell Canc C. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. J Clin Oncol. 2021;39(14):1563-1574. doi:10.1200/JCO.20.03296. IF:44,54.
  • Strauss SJ, Frezza AM, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, de Álava E, Dei Tos AP, Garcia Del Muro X, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Gaspar N, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Gronchi A, Haas R, Hassan AB, Hecker Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, López Pousa A, Martin Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morland B, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Sundby Hall K, Trama A, Unk M, van de Sande M, van der Graaf W, van Houdt WJ, Frebourg T, Ladenstein R, Casali PG, Stacchiotti S, PAEDCAN. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2021;32(12):1520-1536. doi:10.1016/j.annonc.2021.08.1995. IF:32,98.
  • Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, De Álava E, Del Muro XG, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hecker Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez Pousa A, Martin Broto J, Merimsky O, Messiou C, Mir O, Montemurro M, Morland B, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Strauss S, Sundby Hall K, Trama A, Unk M, van de Sande M, van der Graaf W, van Houdt WJ, Frebourg T, Casali PG, Stacchiotti S, ESMO Guidelines Committee EAGEAC. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up(?). Ann. Oncol. 2021;32(11):1348-1365. doi:10.1016/j.annonc.2021.07.006. IF:32,98.
  • Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss DE, Blattner M, Worst B, Heilig CE, Beck K, Horak P, Kreutzfeldt S, Paff E, Stark S, Johann P, Selt F, Ecker J, Sturm D, Pajtler KW, Reinhardt A, Wefers AK, Sievers P, Ebrahimi A, Suwala A, Fernandez Klett F, Casalini B, Korshunov A, Hovestadt V, Kommoss FKF, Kriegsmann M, Schick M, Bewerunge Hudler M, Milde T, Witt O, Kulozik AE, Kool M, Romero Perez L, Grunewald TGP, Kirchner T, Wick W, Platten M, Unterberg A, Uhl M, Abdollahi A, Debus J, Lehner B, Thomas C, Hasselblatt M, Paulus W, Hartmann C, Staszewski O, Prinz M, Hench J, Frank S, Versleijen Jonkers YMH, Weidema ME, Mentzel T, Griewank K, de Alava E, Martin JD, Gastearena M, Chang K, Low SYY, Cuevas Bourdier A, Mittelbronn M, Mynarek M, Rutkowski S, Schuller U, Mautner VF, Schittenhelm J, Serrano J, Snuderl M, Buttner R, Klingebiel T, Buslei R, Gessler M, Wesseling P, Dinjens WNM, Brandner S, Jaunmuktane Z, Lyskjaer I, Schirmacher P, Stenzinger A, Brors B, Glimm H, Heining C, Tirado OM, Sainz Jaspeado M, Mora J, Alonso J, del Muro XG, Moran S, Esteller M, Benhamida JK, Ladanyi M, Wardelmann E, Antonescu C, Flanagan A, Dirksen U, Hohenberger P, Baumhoer D, Hartmann W, Vokuhl C, Flucke U, Petersen I, Mechtersheimer G, Capper D, Jones DTW, Frohling S, Pfister SM, von Deimling A. Sarcoma classification by DNA methylation profiling. Nat Commun. 2021;12(1):498-498. doi:10.1038/s41467-020-20603-4. IF:14,92.
  • Lopez Alemany R, Tirado OM. Metastasis Assessment in Ewing Sarcoma Using Orthotopic Xenografts. Methods Mol Biol. 2021;2226201-213. doi:10.1007/978-1-0716-1020-6_16.

Research highlights

PROJECTS

9 Competitive projects
4 Non competitive projects
93 Clinical trials

PUBLISHED WORKS

5 Clinical guidelines

INNOVATION

1 Spin off

Selected projects

  • 20PSJ020. Aptamer-mediated delivery of siRNAs. (INNO20011MART). Importe Concedido:179.841,84€. 2020-2022. IP:MARTINEZ TIRADO,OSCAR.
  • 20MAR001. Molecular analysis of the metastatic process in developmental tumors. (201925-30). FUND.SANT JOAN DE DEU; FUNDACIO IDIBELL; FUNDACIÓ LA MARATÓ DE TV3. Importe Concedido:151.987,79€. 2020-2023. IP:MARTINEZ TIRADO,OSCAR.
  • 21PSJ004. Uso de una quimera para el tratamiento del Sarcoma de Ewing. FUNDACIÓN ALBA PÉREZ. Importe Concedido:100.125,00€. 2021-2022. IP:MARTINEZ TIRADO,OSCAR.
  • 19MEC015. Atacando proteínas de fusión cancerosas mediante el uso de un ejecutor multifuncional basado en tecnologia ARN. (RTI2018-094787-B-I00). MINISTERIO DE CIENCIA E INNOVACIÓN (MICINN). Importe Concedido:121.000,00€. 2019-2022. IP:MARTINEZ TIRADO,OSCAR.
  • 20FIS013. Study of primary and acquired mechanisms of resistance to immune checkpoint inhibitors in advanced cutaneous melanoma. (PI19/01210). ISCIII. Importe Concedido:111.320,00€. 2020-2022. IP:MARTIN LIBERAL,JUAN JESUS.